Methyprylon
From Wikipedia, the free encyclopedia
Methyprylon
|
|
Systematic (IUPAC) name | |
3,3-diethyl-5-methylpiperidine-2,4-dione | |
Identifiers | |
CAS number | |
ATC code | N05 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | C10H17NO2 |
Mol. mass | 183.248 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Protein binding | 60% |
Metabolism | ? |
Half life | 6-16 hours |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Methyprylon is a sedative of the piperidinedione derivative family. This medicine was used for treating insomnia, but is now rarely used as it has been replaced by newer drugs with less side effects, such as benzodiazepines. Methyprylon was withdrawn from the US market in June 1965 and the Canadian market in September 1990.
Side effects can include: Skin rash, fever, depression, ulcers or sores in mouth or throat, unusual bleeding or bruising, confusion, fast heartbeat, respiratory depression, swelling of feet or lower legs, dizziness, drowsiness, headache, double vision, clumsiness, constipation, diarrhea, nausea, vomiting, unusual weakness
[edit] External links
- Contos D, Dixon K, Guthrie R, Gerber N, Mays D (1991). "Nonlinear elimination of methyprylon (noludar) in an overdosed patient: correlation of clinical effects with plasma concentration.". J Pharm Sci 80 (8): 768–71. doi: . PMID 1686463.
- Gwilt P, Pankaskie M, Thornburg J, Zustiak R, Shoenthal D (1985). "Pharmacokinetics of methyprylon following a single oral dose.". J Pharm Sci 74 (9): 1001–3. doi: . PMID 2866242.
- Lomen P, Linet O (1976). "Hypnotic efficacy of triazolam and methyprylon ininsomniac in-patients.". J Int Med Res 4 (1): 55–8. PMID 16792.